Discover how transitioning to iPSC-based allogeneic cell therapies can revolutionize modern healthcare
October 24, 2024
September 30, 2024
July 8, 2024
June 10, 2024
April 4, 2024
Mont-Saint-Guibert, Belgium (April 4, 2023) – ACQUIRED ASSETS FROM ARTISAN BIO INCLUDE ...
October 30, 2023
Mont-Saint-Guibert, Belgium (October 30, 2023) – Cellistic is pleased to announce the ...
October 9, 2023
Mont-Saint-Guibert, Belgium
October 26, 2023
Using iPSC and gene editing technologies to generate immune-cloaked "off-the-shelf" allogeneic ...
February 12, 2024
Our team returned from Advanced Therapies Week 2024 in Miami energized and excited about the ...
November 8, 2023
The ESCGT 30th Annual Congress was once again filled with the pioneering research and idea ...
August 2, 2023
The future of stem cell research starts here, at the ISSCR Annual Meeting, where more than ...
The whitepaper, a collaboration between the Alliance for Regenerative Medicine (ARM) and the ...
In this article, Cellistic's Head of IP, Sergei Kurkin, addresses the critical intellectual ...
July 18, 2023
Editor's note: In this installment of Expert Opinion, Suzanne Snellenberg, PhD, Director of ...
March 30, 2023
As published in Drug Target Review - March/April 2023 Issue Drug Target Review connects with ...
January 30, 2023
How has the cell therapy landscape evolved in the past ten years, particularly in regard to ...
December 8, 2023
"Cracking the genetic engineering for cell therapy case will enable us to start thinking about ...
September 21, 2023
"We're in an exciting age: the tools and techniques we now have open up the field of cell ...
August 3, 2023
"The future promise of allogeneic cell therapies"
Discover how transitioning to iPSC-based allogeneic cell therapies can revolutionize modern ...
June 18, 2024
"Cellistic offers therapeutic developers a new path towards iPSC allogeneic cell therapy ...
)%20(2).png)
).png)
